Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Biochem Pharmacol. 2021 Mar 11;188:114516. doi: 10.1016/j.bcp.2021.114516

Fig. 2.

Fig. 2.

Almonertinib resensitizes ABCB1-overexpressing multidrug-resistant cells to paclitaxel in a concentration-dependent manner. The chemosensitizing effect of almonertinib on paclitaxel resistance mediated by ABCB1 was examined in (A) HEK293 cells transfected with human ABCB1 (MDR1, left panel) and parental HEK293 cells (right panel), (B) ABCB1-overexpressing NCI-ADR-RES cancer cell line (left panel), and its drug-sensitive parental OVCAR-8 cancer cell line (right panel), as well as (C) ABCB1-overexpressing KB-V-1 cancer cell line (left panel) and its drug-sensitive parental KB-3-1 cancer cell line (right panel). Cells were treated with various concentrations of paclitaxel in the presence of DMSO (open squares) or almonertinib at 50 nM (closed squares), 100 nM (open circles), 200 nM (closed circles), or 500 nM (open triangles). Points, mean values from at least three independent experiments; bars; S.E.M.